Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCTZ Add-on to Olmesartan/Amlodipine in Hypertension
NCT00902538Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of hydrochlorothiazide in essential hypertension (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in Seated Diastolic Blood Pressure at 16 weeks. Started Apr 2009; status: completed.
02
Drugs
hydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00902538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00902538.